|Dr. Steven A. Victor M.D.||Chairman and Chief Exec. Officer||290k||N/A||65|
|Mr. John Huber III||Interim Chief Financial Officer||N/A||N/A||N/A|
|Mr. Leonard A. Mazur||Interim Chief Operating Officer and Director||N/A||N/A||71|
|Ms. Anna Rhodes||Exec. VP of Operations||N/A||N/A||N/A|
|Ms. Sarah R. Young||Director of Quality Assurance||N/A||N/A||N/A|
IntelliCell BioSciences, Inc. operates as a regenerative medicine company in the United States. It develops and commercializes regenerative medicine using adult autologous stromal vascular fraction cells derived from the blood vessels in adipose tissue. The companys products are intended to treat various clinical conditions, such as aesthetic conditions, orthopedic and sports injuries, and pain, as well as cardiac, gastrointestinal, periodontal, and autistic disorders. It also focuses on undertaking clinical studies in partnership with universities and hospitals for osteoarthritis, gum regeneration, non-healing diabetic ulcers, multiple sclerosis, cartilage regeneration, tendon repair, facial lines and wrinkles, chronic migraine headache, bone regeneration, and hair regeneration indications. In addition, the company is involved in sourcing, selling, and distributing laboratory equipment and supplies, which are used in tissue processing activities. It also licenses its products in Canada, Australia, New Zealand, and Thailand. The company has a collaboration agreement with Hielscher Ultrasonics to develop closed processing system for cell therapy manufacturing. IntelliCell BioSciences, Inc. is based in New York, New York.
IntelliCell BioSciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.